TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27031376

Group type: EXPERIMENTAL
Intervention: Spectral CT with 350 mgI kg(-1) contrast injection
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard 120 kVp with 500 mgI kg(-1) contrast
Number of subjects: 50
Study: 25910889

Group type: EXPERIMENTAL
Intervention: Laryngoscopy (L group)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control (C group)
Number of subjects: 84
Study: 23306077

Group type: EXPERIMENTAL
Intervention: Culturally modified DASH intervention (2 individual and 9 group sessions)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (1 individual session and printed DASH educational materials)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 25
Study: 21087825

Group type: EXPERIMENTAL
Intervention: Intravenous arginine (30 g for 5 days)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (25.2 g of alanine for 5 days)
Number of subjects: 35
Study: 18503398

Group type: EXPERIMENTAL
Intervention: Warfarin 5.75 mg once/day (uniform dosage)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Warfarin 7.5 mg/day on Mondays and Fridays and 5 mg/day on each of the remaining days (nonuniform dosage)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both uniform and nonuniform regimens
Number of subjects: 20
Study: 16464923

Group type: EXPERIMENTAL
Intervention: Accurate and empathetic movie portrayal of schizophrenia
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Educational trailer following the movie
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Entertainment and educational value of the movie
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Group who watched a trailer prior to the movie
Number of subjects: 165
Study: 12905468

Group type: EXPERIMENTAL
Intervention: Infliximab (3 mg/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10699472

Group type: EXPERIMENTAL
Intervention: Advice to maintain normal pattern of hair washing (group 2)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Advice not to wash hair during treatment (group 1)
Number of subjects: 109
Study: 9336364

Group type: EXPERIMENTAL
Intervention: 125 mg/m2 IDEC-C2B8
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 250 mg/m2 IDEC-C2B8
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 375 mg/m2 IDEC-C2B8
Number of subjects: 20
Study: 8186669

Group type: EXPERIMENTAL
Intervention: Outpatient treatments for marijuana dependence
Number of subjects: 167
Study: 3533670

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg, t.d.)
Number of subjects: 21
Study: 29143161

Group type: COMPARATOR
Intervention: Clinical assessment (CA)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CA + BNP
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CA + ECHO
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CA + ECHO + BNP
Number of subjects: 44
Study: 28058262

Group type: EXPERIMENTAL
Intervention: PEEP 10 (10 cm H2O)
Number of subjects: 49

Group type: COMPARATOR
Intervention: PEEP 0 (no positive end-expiratory pressure)
Number of subjects: 49
Study: 24531025

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 33

Group type: COMPARATOR
Intervention: Macular laser therapy
Number of subjects: 33
Study: 22509690

Group type: EXPERIMENTAL
Intervention: Low-dose prednisone
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: High-dose prednisone
Number of subjects: 54

Group type: COMPARATOR
Intervention: No prednisone
Number of subjects: 54
Study: 21033120

Group type: EXPERIMENTAL
Intervention: Systemic red light therapy, once a day, 30 minutes until wounds recovered.
Number of subjects: 138

Group type: COMPARATOR
Intervention: Routine therapy (Control group)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Systemic red light therapy
Number of subjects: 138
Study: 18689807

Group type: EXPERIMENTAL
Intervention: GlideScope
Number of subjects: 203

Group type: COMPARATOR
Intervention: Direct Laryngoscopy
Number of subjects: 203
Study: 16476542

Group type: EXPERIMENTAL
Intervention: 60 min OLV (Group B)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 90 min OLV (Group C)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 120 min OLV (Group D)
Number of subjects: 132

Group type: COMPARATOR
Intervention: No OLV (Group A)
Number of subjects: 132
Study: 14560187

Group type: EXPERIMENTAL
Intervention: ProDisc
Number of subjects: 39

Group type: COMPARATOR
Intervention: Lumbar fusion
Number of subjects: 39
Study: 10840304

Group type: EXPERIMENTAL
Intervention: Standard reusable single‐lumen sphincterotome (group A, n = 38)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Disposable triple‐lumen sphincterotome with a guidewire (group B, n = 39)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Cost per patient for reusable sphincterotome
Number of subjects: 77

Group type: COMPARATOR
Intervention: Cost per patient for disposable sphincterotome
Number of subjects: 77
Study: 9124659

Group type: EXPERIMENTAL
Intervention: Intermittent thermodilution cardiac output measurement
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Continuous thermodilution cardiac output measurement
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intermittent and continuous cardiac output measurements
Number of subjects: 12
Study: 7681894

Group type: EXPERIMENTAL
Intervention: Dipyridamole (PDE inhibitor)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Glyceryl trinitrate (GTN) patches, 10 mg/24 h
Number of subjects: 12
Study: 3752480

Group type: EXPERIMENTAL
Intervention: Isoflurane (0.5-1.5 Vol%)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Neurolept analgesia
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 24
Study: 31252275

Group type: EXPERIMENTAL
Intervention: Psychological interventions
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Barriers identified by trialists
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Journals' endorsement of reporting guidelines
Number of subjects: 50
Study: 27740475

Group type: EXPERIMENTAL
Intervention: PatchMatch Filter (PMF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-scale PMF algorithm
Number of subjects: 0
Study: 26420590

Group type: EXPERIMENTAL
Intervention: Calcium supplements (1 g/d)
Number of subjects: 100
Study: 23743397

Group type: EXPERIMENTAL
Intervention: Acetaminophen (APAP), 1,000 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 21649830

Group type: EXPERIMENTAL
Intervention: Home-use hydrogen peroxide bleaching agents (PolaDay 7.5%, PolaDay 9.5%, DayWhite ACP-7.5%, DayWhite ACP 9.5%) and in-office agents (PolaOffice 35%, Opalescence XtraBoost 38%) applied for 30 minutes/day for 21 days or in one session a week for 3 weeks.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: DayWhite ACP-7.5%
Number of subjects: 10
Study: 20001836

Group type: EXPERIMENTAL
Intervention: Ping On ointment
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 16491462

Group type: EXPERIMENTAL
Intervention: Abdominal drainage
Number of subjects: 120

Group type: COMPARATOR
Intervention: No abdominal drainage
Number of subjects: 120
Study: 15536462

Group type: EXPERIMENTAL
Intervention: St John's wort (300 mg three times daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Imipramine (50 mg three times daily)
Number of subjects: 16
Study: 11699402

Group type: EXPERIMENTAL
Intervention: Cefpirome (CPO) 2 g x 2/day
Number of subjects: 208

Group type: COMPARATOR
Intervention: Piperacillin-tazobactam (PT) 4 g x 3/day
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Cefpirome (CPO)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Piperacillin-tazobactam (PT)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Cefpirome (CPO) and Piperacillin-tazobactam (PT)
Number of subjects: 208
Study: 9232213

Group type: EXPERIMENTAL
Intervention: Cholecystokinin tetrapeptide (CCK‐4) 50 micrograms
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 8501490

Group type: EXPERIMENTAL
Intervention: Bone Marrow Transplantation (BMT)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Autologous Bone Marrow Transplantation (ABMT)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Sequential Postremission Chemotherapy (SPC)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Nonrandomized (NR) patients
Number of subjects: 161
Study: 3552835

Group type: EXPERIMENTAL
Intervention: Streptokinase (SK)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 0
Study: 31328929

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: PTSD-focused individual psychotherapy
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: PTSD-focused group psychotherapy
Number of subjects: 265
Study: 29450870

Group type: EXPERIMENTAL
Intervention: Low glycemic index diet
Number of subjects: 350

Group type: COMPARATOR
Intervention: Medication group (propranolol, amitriptyline, flunarizine, topiramate)
Number of subjects: 350
Study: 26331608

Group type: EXPERIMENTAL
Intervention: Basal or poststimulated 17OHP ≥30 nmol/l (group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Poststimulated 17OHP <30 nmol/l (group B)
Number of subjects: 40
Study: 25397800

Group type: EXPERIMENTAL
Intervention: 0.7-mm machined-collar implants
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 1.5-mm machined-collar implants
Number of subjects: 25
Study: 22992358

Group type: EXPERIMENTAL
Intervention: Partially tailored mailed intervention based on the Precaution Adoption Process Model, delivered over 3 years to parents and children.
Number of subjects: 677

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 677
Study: 20672994

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) once-daily (QD) with tenofovir DF and emtricitabine
Number of subjects: 664

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r) twice-daily (BID) with tenofovir DF and emtricitabine
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) once-daily (QD)
Number of subjects: 664

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r) twice-daily (BID)
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) QD
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) QD and BID
Number of subjects: 664
Study: 18833864

Group type: EXPERIMENTAL
Intervention: Finished ion-releasing resin composite at pH 5.0 and 5.5
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unfinished ion-releasing resin composite at pH 5.5
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Finished ion-releasing resin composite
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unfinished ion-releasing resin composite
Number of subjects: 0
Study: 16011391

Group type: EXPERIMENTAL
Intervention: Working alliance
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Treatment satisfaction
Number of subjects: 600
Study: 12477673

Group type: EXPERIMENTAL
Intervention: P6 acupressure (n = 135)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Pressure on bilateral non-acupressure points (n = 139)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Reference group (n = 136)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Vaginal cases (P6 acupressure)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery group (P6 acupressure)
Number of subjects: 410
Study: 10715372

Group type: COMPARATOR
Intervention: Acidform with 0% N‐9
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Acidform with 2.5% N‐9
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Acidform with 5% N‐9
Number of subjects: 18
Study: 7718383

Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg kg‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg kg‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (non-cannulated upper limb)
Number of subjects: 40
Study: 1791565

Group type: COMPARATOR
Intervention: Removable Partial Denture (RPD)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Fixed Partial Dentures (FPD)
Number of subjects: 228
Study: 7234688

Group type: EXPERIMENTAL
Intervention: Ferric sulfate aerosol exposure at a nominal concentration of 75 microgram/m3 (20 microgram iron/m3) for 2 hours
Number of subjects: 38

Group type: COMPARATOR
Intervention: Clean air (sham) exposure for 2 hours
Number of subjects: 38
Study: 30004141

Group type: EXPERIMENTAL
Intervention: Regulations limiting exposure to unwanted drones; specific details on dosage and duration not applicable.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regulations hampering drones used for public safety; specific details on dosage and duration not applicable.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regulations protecting personal privacy; specific details on dosage and duration not applicable.
Number of subjects: 0
Study: 30290902

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin at 1.8 mg/kg via intravenous infusion once every 3 weeks for up to 16 cycles (recommended phase 2 dose).
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin at 1.8 mg/kg.
Number of subjects: 36
Study: 26192078

Group type: EXPERIMENTAL
Intervention: Training and support interventions for care staff
Number of subjects: 119
Study: 25209438

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vertical banded gastroplasty
Number of subjects: 0
Study: 22220931

Group type: EXPERIMENTAL
Intervention: Berberine (300 mg, t.i.d., for 30 days)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Berberine
Number of subjects: 130
Study: 21070197

Group type: EXPERIMENTAL
Intervention: Skin protection cushion (SPC)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Segmented foam cushion (SFC)
Number of subjects: 232
Study: 17112401

Group type: EXPERIMENTAL
Intervention: TAU+OT (treatment as usual plus occupational therapy)
Number of subjects: 62

Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 62
Study: 16148823

Group type: EXPERIMENTAL
Intervention: High-dose epinephrine (0.1 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-dose epinephrine
Number of subjects: 0
Study: 11949897

Group type: EXPERIMENTAL
Intervention: Early training (ET) - 16 weeks of training involving drawing common objects and highlighting the relation between pictures and their referents.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Late training (LT) - Placebo version of training for 16 weeks followed by actual training for 4 weeks in the fifth month.
Number of subjects: 16
Study: 10983527

Group type: EXPERIMENTAL
Intervention: 10 mg/kg single dose
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: 10 mg/kg two doses on 2 consecutive days
Number of subjects: 134
Study: 7483385

Group type: EXPERIMENTAL
Intervention: Chronotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 1976576

Group type: EXPERIMENTAL
Intervention: Sulphasalazine treatment for four weeks
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid treatment for four weeks
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo treatment after sulphasalazine
Number of subjects: 9
Study: 7241460

Group type: EXPERIMENTAL
Intervention: Pressure therapy
Number of subjects: 0
Study: 30392872

Group type: EXPERIMENTAL
Intervention: Breath-enhanced nebulizer
Number of subjects: 107

Group type: COMPARATOR
Intervention: Conventional jet nebulizer
Number of subjects: 107

Group type: COMPARATOR
Intervention: Conventional jet nebulizer (subgroup analysis)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Breath-enhanced nebulizer (subgroup analysis)
Number of subjects: 107
Study: 28669278

Group type: EXPERIMENTAL
Intervention: Solifenacin for 7 days in the study group (n = 165)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Control group (placebo, n = 150)
Number of subjects: 315
Study: 25917659

Group type: EXPERIMENTAL
Intervention: Food insecurity
Number of subjects: 0
Study: 23333663

Group type: EXPERIMENTAL
Intervention: Teduglutide 0.05 mg/kg/d
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Teduglutide 0.10 mg/kg/d
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Teduglutide (both doses)
Number of subjects: 52
Study: 21407126

Group type: EXPERIMENTAL
Intervention: MD + fructose (2:1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MD + galactose (2:1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: MD + glucose (2:1)
Number of subjects: 10
Study: 19192472

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 1068

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 1068

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 1068
Study: 17365203

Group type: EXPERIMENTAL
Intervention: Individualized asthma education session (group 1)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Reinforced asthma education (group 2)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Reinforced asthma education plus case management (group 3)
Number of subjects: 212
Study: 15586183

Group type: EXPERIMENTAL
Intervention: Psycho-educative group-based treatment programme (8 weeks, weekly sessions of 2.5 hours, booster sessions after 1, 2, and 4 months)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 155
Study: 16283926

Group type: EXPERIMENTAL
Intervention: Bright green light (1,200 Lux)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Dim red light placebo (<10 Lux)
Number of subjects: 33
Study: 10353380

Group type: EXPERIMENTAL
Intervention: HIV seropositive participants on Stroop task
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Paper-and-pencil version of the Stroop task
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Stroop-RT version of the Stroop task
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Blocking manipulation on Stroop-RT
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: HIV infection
Number of subjects: 72
Study: 8595765

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 388
Study: 1849159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Peroral ACV (started 7 days before or 5 min after UVR)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Peroral ACV (started 48 h after UVR)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Topical ACV (started 5 min after UVR)
Number of subjects: 196
Study: 6277698

Group type: EXPERIMENTAL
Intervention: Cyclic estrogen regimen (0.625 mg of conjugated estrogens, 3 weeks on, 1 week off)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Continuous estrogen regimen (0.625 mg of conjugated estrogens, daily)
Number of subjects: 25
Study: 29509315

Group type: EXPERIMENTAL
Intervention: Lean-seafood diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-seafood diet
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 20
Study: 28705181

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 0
Study: 26682998

Group type: EXPERIMENTAL
Intervention: Omega-3 and omega-6 supplements for 12 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 23860544

Group type: EXPERIMENTAL
Intervention: Teaching emotional intelligence
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 52
Study: 21182509

Group type: EXPERIMENTAL
Intervention: FSL phototherapy (twice per week for 4 weeks)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: FSL phototherapy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (emollient application only)
Number of subjects: 38
Study: 19947442

Group type: EXPERIMENTAL
Intervention: Arthrofoon
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sublingual nimesulide
Number of subjects: 50
Study: 17511722

Group type: EXPERIMENTAL
Intervention: PSA-based screening
Number of subjects: 3758

Group type: EXPERIMENTAL
Intervention: PSA < 4 ng/mL with doubtful DRE finding
Number of subjects: 3758

Group type: EXPERIMENTAL
Intervention: Conventional systematic sextant biopsies
Number of subjects: 3758
Study: 15322648

Group type: EXPERIMENTAL
Intervention: RS system packing method
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional packing method
Number of subjects: 40
Study: 11437873

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine (10 mL h(‐1))
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine (10 mL h(‐1))
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with 0.5 microg mL(‐1) sufentanil (BS)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine with 0.5 microg mL(‐1) sufentanil (RS)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 0.5 microg mL(‐1) sufentanil only (S)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine plus sufentanil
Number of subjects: 109
Study: 9881243

Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sulphonylurea treatment
Number of subjects: 37
Study: 8275737

Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted breathing retraining (BRT) with pneumographic or strain-gauge feedback and electromyogram feedback, 8 sessions.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group received biofeedback-assisted (hand warming) relaxation training.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted breathing retraining (BRT)
Number of subjects: 26
Study: 31395416

Group type: EXPERIMENTAL
Intervention: Higher birth weight (third quintile)
Number of subjects: 1669

Group type: EXPERIMENTAL
Intervention: Higher birth weight (fourth quintile)
Number of subjects: 1669

Group type: EXPERIMENTAL
Intervention: Higher birth weight (top quintile)
Number of subjects: 1669

Group type: EXPERIMENTAL
Intervention: Birth weight in higher three quintiles
Number of subjects: 1669

Group type: COMPARATOR
Intervention: Reference group (second quintile of birth weight)
Number of subjects: 1669
Study: 28943321

Group type: EXPERIMENTAL
Intervention: CPAP group (M1)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: O2 flow group (M2)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Air flow group (M3)
Number of subjects: 181